Highly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples. II. Albumin in body fluids of patients with neurological disorders.
We have previously used the molecular-imprinting method for the synthesis of artificial gel antibodies, highly selective for various proteins. In the present work, we have synthesized artificial gel antibodies against human albumin with the aim to develop a simple and rapid procedure to measure the concentration of this protein in samples of clinical interest. The procedure, based on the design of a standard curve (see the preceding paper), was applied on a quantitative analysis of albumin in human plasma and cerebrospinal fluid (CSF). We found that our technique permitted detection of albumin in these body fluids with high precision and that the concentration of this protein was significantly enhanced in CSF from patients with amyotrophic lateral sclerosis (ALS), compared to control samples. This finding is in agreement with results from earlier studies, which confirms the validity of our analysis technique and suggests that the barrier permeability may be affected in ALS, perhaps also for other proteins. No enhancement in plasma levels of albumin was seen in patients with ALS, but rather a decrease. The results further indicate that our approach might also apply well to other biomarkers for the actual neurological disease and other disorders.
Ghasemzadeh
Nasim
N
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Nyberg
Fred
F
Hjertén
Stellan
S
D000690:Amyotrophic Lateral Sclerosis / Q000097:blood* / Q000134:cerebrospinal fluid*; D000906:Antibodies / Q000276:immunology*; D015415:Biomarkers / Q000097:blood* / Q000134:cerebrospinal fluid*; D002138:Calibration; D016022:Case-Control Studies; D006801:Humans; D012015:Reference Standards; D012680:Sensitivity and Specificity; D012709:Serum Albumin / Q000032:analysis* / Q000134:cerebrospinal fluid*
D000906:Antibodies; D015415:Biomarkers; D012709:Serum Albumin